Grace Therapeutics reports Q3 FY2026 net loss of $2.3M; cash $18.7M; FDA PDUFA date April 23, 2026 for GTx-104

Grace Therapeutics, Inc.

2026-Q3 EPS reported -$0.41

Net loss of $2.3M ($0.14 per share) improved from $4.2M loss ($0.36 per share) in prior year quarter.
FDA set April 23, 2026 as PDUFA target date for GTx-104 NDA for aSAH treatment.
Cash and equivalents $18.7M as of Dec 31, 2025; company believes sufficient for 12+ months.
Phase 3 STRIVE-ON trial data presented; GTx-104 showed 19% reduction in hypotension vs. oral nimodipine.
Raised $4.0M through warrant exercises at $3.003/share; 1.35M shares issued.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.